Laser in situ keratomileusis for hyperopia.
OBJECTIVE
To evaluate the results of laser in situ keratomileusis (LASIK) to treat hyperopia.


METHODS
Instituto de la Vision, Buenos Aires, Argentina.


METHODS
This nonrandomized study comprised 679 eyes of 321 patients having LASIK. Patients were divided into three groups based on preoperative spherical equivalent: Group A (low hyperopia, 2.00 diopters [D] or less); Group B (moderate hyperopia, between 2.00 and 3.00 D); Group C (high hyperopia, more than 3.00 D). The following were measured postoperatively: uncorrected visual acuity (UCVA); best spectacle-corrected visual acuity (BSCVA); refraction (evolution and distribution); lines of visual acuity gained and lost. Follow-up was 1 month in 79.4% of cases, 3 months in 75.5%, 6 months in 68.5% and 1 year in 38.3%.


RESULTS
Six months after LASIK. 100% of cases in Group A, 95.3% in Group B, and 71.4% in Group C were within +/- 1.00 D of emmetropia; UCVA was 20/40 or better in 94.1, 100, and 87.8%, respectively. The percentage losing or gaining 0 +/- 1 line of BSCVA was 100, 97.6, and 100, respectively.


CONCLUSIONS
Laser in situ keratomileusis was predictable and safe in the treatment of low and moderate hyperopia.
Instituto de la Vision, Buenos Aires, Argentina.
C J
CJ
Argento
M J
MJ
Cosentino
D000328:Adult; D001251:Astigmatism / Q000503:physiopathology; D019781:Corneal Topography; D016039:Corneal Transplantation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006956:Hyperopia / Q000503:physiopathology / Q000601:surgery*; D007431:Intraoperative Complications; D053685:Laser Therapy; D008297:Male; D012029:Refraction, Ocular; D012449:Safety; D016896:Treatment Outcome; D014792:Visual Acuity